脑脊液生化标志物在常规临床实践中对痴呆症的早期检测及鉴别诊断中的应用

Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice.

作者信息

Parnetti L, Lanari A, Saggese E, Spaccatini C, Gallai V

机构信息

Memory Clinic, Alzheimer Center, Department of Neuroscience, University of Perugia, Perugia, Italy.

出版信息

Neurol Sci. 2003 Oct;24(3):199-200. doi: 10.1007/s10072-003-0129-8.

DOI:10.1007/s10072-003-0129-8

PMID:14598086

Abstract

Measurement of total tau and amyloid beta1-42 (Ab42) in cerebrospinal fluid (CSF) improves diagnostic accuracy of Alzheimer's disease (AD). We examined a consecutive patient sample referred to our center for diagnostic assessment of cognitive decline. CSF tau and Abeta42 were assayed each week as routine neurochemical analyses. There were 119 patients investigated. These included 61 with probable AD (35 mild AD, 26 severe AD), 24 with mild cognitive impairment (MCI), 14 with vascular dementia, 11 with Lewy body dementia, and 9 with fronto-temporal dementia. Mild AD showed significantly lower CSF Abeta42 levels and significantly higher CSF tau levels than the other diagnostic groups; 79% of MCI patients had pathological values for both biomarkers. We confirm that these biomarkers have a role in the clinical work-up of patients with cognitive deficits.

摘要

测量脑脊液（CSF）中的总tau蛋白和β淀粉样蛋白1-42（Ab42）可提高阿尔茨海默病（AD）的诊断准确性。我们对连续转诊至本中心进行认知功能减退诊断评估的患者样本进行了检查。每周对脑脊液tau蛋白和Abeta42进行检测，作为常规神经化学分析。共调查了119例患者。其中包括61例可能患有AD的患者（35例轻度AD，26例重度AD）、24例轻度认知障碍（MCI）患者、14例血管性痴呆患者、11例路易体痴呆患者和9例额颞叶痴呆患者。与其他诊断组相比，轻度AD患者的脑脊液Abeta42水平显著降低，脑脊液tau蛋白水平显著升高；79%的MCI患者这两种生物标志物的值均为病理性。我们证实这些生物标志物在认知功能缺损患者的临床检查中具有作用。